Synthesis and biological studies of new quinazolines with ether functions in position 2

Brahmaiah, Dabbugoddu; Bhavani, A. K. D.; Aparna, P.; Kumar, Nangunoori Sampath; Solhi, Hélène; Guével, Rémy Le; Baratte, Blandine; Ruchaud, Sandrine; Bach, Stéphane; Mosset, Paul; Grée, René

doi:10.24820/ark.5550190.p010.859

Cited by 2 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our research group has studied new series of triazolylquinazolines-2-triazolylalkoxyquinazolines and 8-triazolylalkoxyquinazolines as MmCLK1, CLK1 kinases inhibitors. Most of those compounds did not show any significant cytotoxicity against HuH7, CaCo-2, MDA-MB231, HCT116, PC3, NCI-H727, and MCF7 cancer cell lines [14,15]. Up to date, cytotoxicity of quinazoline-triazole hybrids has not been tested against brain cancer cell lines, for which reason we have carried out synthesis of such compounds and tested their certain activity.…”

Section: Introductionmentioning

confidence: 98%

Synthesis and Cytotoxic Studies of Quinazoline-Triazole Hybrid Aza Heterocycles

et al. 2021

Self Cite

View full text Add to dashboard Cite

Herein, we report a series of 1,2,3-triazole combined with quinazoline hybrid heterocyclic compounds by 1,3-dipolar cycloaddition reaction catalyzed by Cu(I). This reaction has been carried out between quinazoline based alkyne and aryl/benzyl azides under optimized conditions. Modification of 4-hydroxyquinazoline by propargyl bromide in presence of potassium carbonate gives a corresponding alkyne. Structure of the synthesized compounds has been characterized by IR, 1 H, and 13 C NMR, ESI-Mass, and HRMS spectra. The products have been tested for anticancer activity against C6 glioma cell lines and characterized by moderate cytotoxic activity.

show abstract

Section: Introductionmentioning

confidence: 98%

Synthesis and Cytotoxic Studies of Quinazoline-Triazole Hybrid Aza Heterocycles

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

Discovery of DB18, a potent inhibitor of CLK kinases with a high selectivity against DYRK1A kinase

Brahmaiah

Bhavani²,

Aparna³

et al. 2021

Bioorganic & Medicinal Chemistry

Self Cite

View full text Add to dashboard Cite

We describe in this paper the synthesis of a novel series of anilino-2-quinazoline derivatives. These compounds have been screened against a panel of eight mammalian kinases and in parallel they were tested for cytotoxicity on a representative panel of seven cancer cell lines. One of them (DB18) has been found to be a very potent inhibitor of human "CDC2-like kinases" CLK1, CLK2 and CLK4, with IC 50 values in the 10-30 nM range. Interestingly, this molecule is inactive at 100M on the closely related "dualspecificity tyrosine-regulated kinase 1A" (DYRK1A). Extensive molecular simulation studies have been performed on the relevant kinases to explain the strong affinity of this molecule on CLKs, as well as its selectivity against DYRK1A.

show abstract

Synthesis and biological studies of new quinazolines with ether functions in position 2

Cited by 2 publications

References 9 publications

Synthesis and Cytotoxic Studies of Quinazoline-Triazole Hybrid Aza Heterocycles

Synthesis and Cytotoxic Studies of Quinazoline-Triazole Hybrid Aza Heterocycles

Discovery of DB18, a potent inhibitor of CLK kinases with a high selectivity against DYRK1A kinase

Contact Info

Product

Resources

About